Combination therapy with notch and PD-1 or PD-L1 inhibitors
The present invention provides medicaments for use in treating and methods of treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, chronic lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, erythroleukemia, triple negative breast cancer, breast cancer, ovarian cancer, melanoma, Sung cancer, non small-cell lung cancer, pancreatic cancer, glioblastoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, oral squamous cell carcinoma, skin cancer, medul!ob!astoma, hepatocellular carcinoma, intrahepatic and extrahepatic cholangiocarcinoma, desmoid tumor, soft tissue sarcoma, or adenoid cystic carcinoma in a patient comprising combination therapy with 4,4,4-tri-fluoro-N-[(1S)-2˜[[(7S)-5-(2-hydroxyemyl)-6-oxo-7H-pyrido[23-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyljbutanamide, or a pharmaceutically acceptable salt or hydrate thereof, and a PD-1 or a PD-L1 inhibitor selected from pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab.
1. A method of treating colorectal cancer, comprising
administering to a patient in need of treatment of a cancer an effective amount of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and an effective amount of an anti-PD-1 or anti-PD-L1 antibody inhibitor.
2. The method of claim 1 , wherein between 2.5 mg and 75 mg of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered.
3. The method of claim 1 , wherein between 10 mg and 50 mg of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3 -d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered.
4. The method of claim 1 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered once per day every other day over a five day period followed by two days without administration (T.I.W.).
5. The method of claim 1 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered once per day (QD), twice per day (B.I.D.), once per day every other day (Q2D), or once every third day (Q3D).
6. The method of claim 1 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7 -yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered orally.
7. The method of claim 1 , wherein between 1 mg/kg and 3 mg/kg of the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered.
8. The method of claim 2 , wherein between 1 mg/kg and 3 mg/kg of the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered.
9. The method of claim 1 , wherein the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered once every 14 to 21 days.
10. The method of claim 2 , wherein the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered once every 14 to 21 days.
11. The method of claim 1 , wherein the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered parenterally.
12. The method of claim 1 , wherein the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered by intravenous infusion.
13. The method of claim 1 , wherein between 2.5 mg and 75 mg of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered, and between 1 mg/kg and 3 mg/kg of the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered.
14. The method of claim 1 , wherein between 10 mg and 50 mg of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered, and between 1 mg/kg and 3 mg/kg of the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered.
15. The method of claim 13 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7 -yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered once per day every other day over a five day period followed by two days without administration (T.I.W.), and the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered once every 14 to 21 days.
16. The method of claim 14 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido [2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered once per day every other day over a five day period followed by two days without administration (T.I.W.), and the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered once every 14 to 21 days.
17. The method of claim 13 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7 -yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof is administered orally, and the anti-PD-1 or anti-PD-L1 antibody inhibitor is administered intravenously.
18. The method of claim 1 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7 -yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof and the anti-PD-1 or anti-PD-L1 antibody inhibitor are administered simultaneously, separately, or sequentially.
19. The method of claim 13 , wherein 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof and the anti-PD-1 or anti-PD-L1 antibody inhibitor are administered simultaneously, separately, or sequentially.